“Identification of biorelevant dissolution media to assess biopharmaceutical performance of erlotinib formulation with enhanced bioavailability using physiologybased pharmacokinetic modeling”, AJP, vol. 16, no. 2, Jun. 2022, doi: 10.22377/ajp.v16i2.4389.